These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 22285623)

  • 1. Does expression of the retrogene UTP14c in the ovary pre-dispose women to ovarian cancer?
    Rohozinski J; Edwards CL; Anderson ML
    Med Hypotheses; 2012 Apr; 78(4):446-9. PubMed ID: 22285623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UTP14c is a recently acquired retrogene associated with spermatogenesis and fertility in man.
    Rohozinski J; Lamb DJ; Bishop CE
    Biol Reprod; 2006 Apr; 74(4):644-51. PubMed ID: 16354793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers.
    Rohozinski J; Anderson ML; Broaddus RE; Edwards CL; Bishop CE
    PLoS One; 2009; 4(3):e5064. PubMed ID: 19333399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
    Corney DC; Flesken-Nikitin A; Godwin AK; Wang W; Nikitin AY
    Cancer Res; 2007 Sep; 67(18):8433-8. PubMed ID: 17823410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA expression profiles in serous ovarian carcinoma.
    Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
    Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
    Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
    Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
    Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
    Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.
    Mezzanzanica D; Balladore E; Turatti F; Luison E; Alberti P; Bagnoli M; Figini M; Mazzoni A; Raspagliesi F; Oggionni M; Pilotti S; Canevari S
    Clin Cancer Res; 2004 Aug; 10(15):5202-14. PubMed ID: 15297424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
    Guo LM; Pu Y; Han Z; Liu T; Li YX; Liu M; Li X; Tang H
    FEBS J; 2009 Oct; 276(19):5537-46. PubMed ID: 19702828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium.
    Neyns B; Katesuwanasing ; Vermeij J; Bourgain C; Vandamme B; Amfo K; Lissens W; DeSutter P; Hooghe-Peters E; DeGrève J
    Oncogene; 1996 Mar; 12(6):1247-57. PubMed ID: 8649827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
    Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
    Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of dicer expression in ovarian cancer tissues.
    Pampalakis G; Diamandis EP; Katsaros D; Sotiropoulou G
    Clin Biochem; 2010 Feb; 43(3):324-7. PubMed ID: 19782670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis].
    Li J; Liang SH; Lu X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):787-92. PubMed ID: 21176563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and biologic factors in the pathogenesis of ovarian cancer.
    Berek JS; Martínez-Maza O
    J Reprod Med; 1994 Apr; 39(4):241-8. PubMed ID: 8040839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
    Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
    Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer.
    Arcand SL; Provencher D; Mes-Masson AM; Tonin PN
    Int J Oncol; 2005 Nov; 27(5):1315-20. PubMed ID: 16211227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.